sph5030
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 21, 2022 (NCT05245058)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2ANTAGONIST
ERBB2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06434597 | Phase 2 | Jul 17, 2024 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT06372223 | Phase 1 | Mar 4, 2024 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05245058 | Early Phase 1 (Phase 1) | Jan 21, 2022 | Chinese Academy of Medical Sciences, Shanghai Pharmaceuticals Holding Co., Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 3 | 3 | 2 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1